New hope for rare cancers: drug combo trial opens
NCT ID NCT06161532
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 36 times
Summary
This phase 2 trial tests whether the drug sacituzumab govitecan, alone or with atezolizumab, can shrink rare genitourinary tumors like certain bladder, kidney, and penile cancers. About 60 adults will receive the drugs intravenously in 21-day cycles for up to 5 years. The study aims to see how many patients respond and how long they live without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF THE BLADDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab govitecan and atezolizumab
What this could lead to
If successful, this could provide a new treatment option for people with rare genitourinary cancers that are hard to study and have few approved therapies.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The drugs can cause side effects like nausea, fatigue, and immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.